Richter’s syndrome

Clinical research activity is centered on Richter’s syndrome, with particular attention to aggressive transformation of chronic lymphocytic leukaemia into diffuse large B-cell lymphoma. The sponsor’s funded trial landscape reflects interest in first-line treatment strategies for newly diagnosed disease and in immunotherapy combined with standard chemotherapy backbones.

• Diffuse large B-cell lymphoma-Richter syndrome
• Chronic lymphocytic leukaemia transformation
• First-line treatment in aggressive B-cell lymphoma
• CD20-directed immunotherapy

The research setting includes multiple collaborating sites in Spain, indicating a coordinated focus on specialised haematology and lymphoma care.